The DOI matches its Crossref record.
A cyclic oligonucleotide signaling pathway in type III CRISPR-Cas systems
Abstract
Bacterial defense amplification: Prokaryotic type III CRISPR systems use the effector complex and additional proteins such as Csm6 to destroy both the genome and the transcripts of invaders. However, how the effector complex and Csm6 coordinate CRISPR activity remains a mystery. Kazlauskiene et al. found that a cyclic oligonucleotide–based signaling pathway can regulate the defense response (see the Perspective by Amitai and Sorek). Upon target recognition, the Cas10 subunit of the effector complex synthesizes cyclic oligoadenylates, which act as second messengers to initiate and amplify the nuclease activity of Csm6. Science , this issue p. 605 ; see also p. 550
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Csm6 is activated by cyclic oligoadenylates and has an auxiliary action by degrading foreign transcripts in a non-specific fashion.
“Csm6 is activated by these oligoadenylates, and even though it is not a part of the Cascade effector complex, it has an auxiliary action by degrading foreign transcripts in a non-specific fashion [51,52].”
From CRISPR-Cas: Converting A Bacterial Defence Mechanism into A State-of-the-Art Genetic Manipulation Tool (2019) · cites this paper as [51]
Cas10 has a further role in activating non-specific RNase Csm6 by producing cyclic oligoadenylates from ATP molecules.
“Recent studies also suggest that Cas10 has a further role in activating non-specific RNase Csm6, by producing cyclic oligoadenylates from ATP molecules.”
From CRISPR-Cas: Converting A Bacterial Defence Mechanism into A State-of-the-Art Genetic Manipulation Tool (2019) · cites this paper as [51]
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 38
- 10.1016/j.tim.2016.09.012 · DOI · Paper page
- 10.1101/gad.273722.115 · DOI
- 10.1016/j.molcel.2016.03.024 · DOI · Paper page
- 10.1371/journal.pone.0170552 · DOI
- 10.1016/j.str.2012.01.018 · DOI
- 10.1186/1745-6150-6-38 · DOI
- 10.1016/j.febslet.2012.02.036 · DOI
- 10.1093/nar/gkv1267 · DOI
- 10.1101/gad.272153.115 · DOI
- 10.1016/j.cell.2015.04.027 · DOI · Paper page
- 10.1016/j.jmb.2013.03.042 · DOI
- 10.1073/pnas.76.10.4788 · DOI
- 10.1080/00021369.1974.10861384 · DOI
- 10.1039/C6CC03439J · DOI
- 10.1042/BST20130038 · DOI · Paper page
- 10.1016/j.molcel.2014.09.027 · DOI
- 10.1261/rna.054098.115 · DOI
- 10.3389/fgene.2014.00102 · DOI
- 10.1261/rna.039842.113 · DOI
- 10.1186/1745-6150-8-15 · DOI
- 10.1016/j.cell.2015.12.053 · DOI
- 10.1038/nature15254 · DOI
- 10.1016/j.jmb.2010.11.019 · DOI
- 10.1080/15476286.2015.1130209 · DOI
- 10.1080/15476286.2015.1051300 · DOI
- 10.1126/science.aaf5573 · DOI · Paper page
- 10.1016/j.cytogfr.2007.06.012 · DOI
- 10.1002/bies.201600186 · DOI
- 10.1093/nar/gnh110 · DOI
- 10.1631/jzus.B0820367 · DOI
- 10.1093/bioinformatics/bti125 · DOI
- 10.1093/nar/gki408 · DOI
- 10.1006/jmbi.1993.1626 · DOI · Paper page
- 10.1016/j.str.2011.09.022 · DOI
- 10.1093/nar/gkr366 · DOI · Paper page
- 10.1002/jcc.20084 · DOI
- 10.1007/s001800200117 · DOI
- 10.1002/prot.24183 · DOI
Cited by
Sorted by citations
Origins and evolution of CRISPR-Cas systems
Koonin, E. V., & Makarova, K. S. (2019) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2018.0087 · Cited by 494
Structural Basis for the RNA-Guided Ribonuclease Activity of CRISPR-Cas13d
Zhang, C., Konermann, S., Brideau, N. J., Lotfy, P., Wu, X., Novick, S. J., Strutzenberg, T., Griffin, P. R., Hsu, P. D., & Lyumkis, D. (2018) · Cell · doi:10.1016/j.cell.2018.09.001 · Cited by 276
CRISPR-Based Technologies: Impact of RNA-Targeting Systems
Terns, M. P. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.09.018 · Cited by 168
Loureiro, A., & da Silva, G. J. (2019) · Antibiotics · doi:10.3390/antibiotics8010018 · Cited by 129
RNA-Targeting CRISPR-Cas systems and their applications
Burmistrz, M., Krakowski, K., & Krawczyk-Balska, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21031122 · Cited by 125
Structural basis of CRISPR-Cas Type III prokaryotic defence systems
Molina, R., Sofos, N., & Montoya, G. (2020) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2020.06.010 · Cited by 48
Guo, T., Zheng, F., Zeng, Z., Yang, Y., Li, Q., She, Q., & Han, W. (2019) · RNA Biology · doi:10.1080/15476286.2019.1642725 · Cited by 11
Metadata
- Authors
- Kazlauskiene, M., Kostiuk, G., Venclovas, Č., Tamulaitis, G., & Siksnys, V.
- Affiliations
- Institute of Biotechnology, Vilnius University, Saulėtekio Avenue 7, 10257 Vilnius, Lithuania.
- Venue
- Science
- Published
- 2017-08-11
- Volume
- 357
- Issue
- 6351
- Pages
- 605-609
- ISSN
- 0036-8075
- 1095-9203
- Cited by
- 521
- References
- 0
- Language
- en
- Funders
- Research Council of Lithuania (award332114, APP-3/2016)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
